DIAKOVERE Krankenhaus gGmbH
- Address
- Marienstrasse 72-90, Suedstadt, 30171 Hanover, Germany
DIAKOVERE Krankenhaus gGmbH - Oncology Research Center
DIAKOVERE Krankenhaus gGmbH is a comprehensive oncology research center with specialized expertise in breast cancer therapeutics and hematologic malignancies. The center demonstrates particular strength in evaluating innovative treatment strategies across multiple cancer types, with a strong focus on targeted therapies and immunotherapy approaches.
- Advanced breast cancer research including HER2-positive, triple-negative, and hormone receptor-positive subtypes
- Novel maintenance and adjuvant therapy strategies for endometrial and gynecologic cancers
- Hematologic malignancies with focus on advanced-stage Hodgkin lymphoma
- Neurodegenerative disease research including amyotrophic lateral sclerosis (ALS)
The center participates in multiple Phase II and III clinical trials evaluating cutting-edge combination therapies, including antibody-drug conjugates, CDK4/6 inhibitors, and PI3K inhibitors. Their research portfolio emphasizes personalized medicine approaches with biomarker-driven treatment selection and neoadjuvant strategies designed to optimize patient outcomes while minimizing treatment-related toxicity. DIAKOVERE's involvement in landmark international trials positions it at the forefront of developing next-generation cancer therapeutics and precision oncology solutions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 1 of 2 therapeutic areas and 15 of 46 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 46 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1Ferrer Internacional S.A.1active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB2trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in DIAKOVERE Krankenhaus gGmbH
lock Showing 1 of 13 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Usnoflast in Adults with Amyotrophic Lateral Sclerosis | Zydus Therapeutics Inc. | Phase II | Recruiting | Jul 2026 | — |
IMP list
lock Showing 1 of 46 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Abemaciclib | 2 | Unknown | 2020-07-23 | 2024-03-25 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.